Participants numbered 3334 and had a median age of 62 years. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Research
30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.
Data on 214 251 respondents were included in the study. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
43/100
Dementia, a syndrome characterized by a decline in cognitive function beyond what is expected from normal aging, poses a significant global health challenge. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The analysis revealed five distinct themes: (1) impact of the program, (2) facilitators enhancing participation, (3) barriers hindering participation, (4) suggestions for improving participation and (5) challenges to adopt digital platforms. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The MI group significantly improved in attention-executive functioning (p = 0.003) compared to ACI (Cohen's d: 0.47, 95% CI 0.13-0.79). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
After adjusting for baseline scores via ANCOVA, the experimental group demonstrated significantly higher post-intervention outcomes compared to the control group (p < 0.001). 5 key findings →
Participants: 58 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Greater perceived control at study baseline was associated with reduced hazard of ADRD. 3 key findings →
Participants: 2,021 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Mild cognitive impairment in Parkinson's disease (PD-MCI) can affect several cognitive domains, including attention, working memory, executive functions, language, visuospatial skills, and episodic memory, resulting in a progressive reduction of autonomy and an increased risk of dementia. 1 key finding →
Design: clinical trial Participants: 23 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Although a substantial proportion of TG participants achieved high MI accuracy values, statistical analyses revealed no cognitive improvements specific to TG, suggesting limited efficacy of the MI-based protocol compared to classical cognitive stimulation. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
42/100
Individuals with Alzheimer’s dementia exhibited poorer nutritional status (EdFED: 8.0 vs. 2.0; NUFFE: 10.0 vs. 7.0; both p < 0.001) and lower adherence to the Mediterranean diet (6.0 vs. 7.0; p = 0.050). 3 key findings →
Participants: 60 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The project is expected to generate evidence on the effectiveness, feasibility, and cost-effectiveness of multidomain interventions implemented across diverse real-world settings, including community, hospital, and long-term care. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Change in QoL (decreased, maintained or improved) was determined using a cross-tabulation test. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Consistent with previous research, transfer gains from the OMT condition to an untrained VM task suggest that olfaction may contribute to a‐modal representations of memory. 3 key findings →
Participants: 53 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Of the 747 studies identified, 6 studies fulfilled the eligibility criterion for this review. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The demographic transition during the recent decades has resulted in an increase in older adults globally. 2 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The Mediterranean diet, rich in plant-based foods, olive oil, and fish, has been consistently associated with slower cognitive decline and reduced risk of neurodegeneration in observational studies and some clinical trials. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Emotion scores for fear and surprise were significantly higher for the AD group than for the MCI group during dual tasks (p=0.016), while emotion scores for joy were significantly higher for the MCI group than for the AD group during creative activities (p=0.012). 4 key findings →
Participants: 14 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
40/100
This study aimed to examine the effects of aerobic and strength training methodologies, either combined with or without cognitive training, on mitigating cognitive decline. 5 key findings →
Participants: 56 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The growing prevalence of dementia emphasizes the need for effective prevention strategies. 4 key findings →
Participants: 289 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The manuscript provides a thorough analysis of the neurovascular and metabolic processes that contribute to cognitive deterioration in patients with Type 2 diabetes (T2D). 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
For the interim analysis as of October 2024, the results of the MCI study arm are reported (n=42). 5 key findings →
Participants: 42 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Each 10% increase in UPF intake was associated with lower attention scores (-0.05 points) and higher dementia risk (+0.24 points), independent of Mediterranean diet adherence. 2 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
40/100
Dementia affects over 55 million people globally, with early cognitive decline, such as Mild Cognitive Impairment (MCI), often preceding neurodegenerative diseases. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Sample characteristics are shown in Table 1. 5 key findings →
Participants: 1,104 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The study determined an adequate sample size (KMO = 0.67), with sufficient item correlations for factor analysis (χ2 = 449.74; p < 0.001). 5 key findings →
Participants: 310 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,042 records (3.4% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events